SLU-PP-332

SLU-PP-332 is a potent, selective pan-estrogen related receptor (ERR) agonist that has emerged as an important research tool for studying metabolic regulation and energy homeostasis. The compound was developed through systematic structure-activity relationship studies aimed at creating selective modulators of the ERR family of orphan nuclear receptors.

The ERR family consists of three members—ERRα, ERRβ, and ERRγ—which are constitutively active transcription factors that regulate genes involved in oxidative metabolism, mitochondrial biogenesis, and energy expenditure. Unlike traditional estrogen receptors, ERRs do not bind estrogen but instead share some target genes with estrogen receptors, hence the "estrogen-related" designation.

Metabolic Significance

ERRs are master regulators of cellular energy metabolism, controlling the expression of genes involved in fatty acid oxidation, oxidative phosphorylation, the citric acid cycle, and mitochondrial biogenesis. ERRα in particular is highly expressed in tissues with high energy demands, including heart, skeletal muscle, brown adipose tissue, and kidney, where it coordinates the expression of metabolic gene networks.

SLU-PP-332 activates all three ERR isoforms with high potency, with EC50 values of approximately 98 nM for ERRα, 230 nM for ERRβ, and 430 nM for ERRγ, making it among the most potent pan-ERR agonists available for research.

Research Applications

In preclinical studies, SLU-PP-332 has demonstrated remarkable effects on metabolism and body composition. Treatment of mice with metabolic syndrome showed increased energy expenditure, enhanced fatty acid oxidation, decreased fat mass, and improved insulin sensitivity—all without changes in food intake. These effects mirror those observed with exercise, leading to interest in ERR agonists as potential "exercise mimetics."

The compound also increases mitochondrial respiration in vitro, consistent with the role of ERRs in regulating mitochondrial function. This has implications for understanding and potentially treating conditions characterized by mitochondrial dysfunction.

SLU-PP-332 functions as an agonist of the estrogen-related receptor (ERR) family, binding directly to ERRα, ERRβ, and ERRγ and enhancing their transcriptional activity. ERRs are members of the nuclear receptor superfamily of ligand-activated transcription factors, though unlike most nuclear receptors, ERRs are constitutively active and were long thought to be "orphan" receptors lacking endogenous ligands.

Receptor Structure and Activation

ERRs share the typical nuclear receptor domain structure, with an N-terminal activation domain, a central DNA-binding domain, and a C-terminal ligand-binding domain (LBD). The LBD of ERRs adopts an active conformation even in the absence of ligand, which is stabilized by interaction with coactivators such as PGC-1α and PGC-1β.

SLU-PP-332 binds to the ligand-binding pocket of ERRs and further stabilizes the active receptor conformation, enhancing coactivator recruitment and transcriptional output. The compound's structure—(E)-4-hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide—allows it to interact favorably with key residues in the ERR ligand-binding pocket.

Transcriptional Programs

Upon activation by SLU-PP-332, ERRs bind to ERR response elements (ERREs) in the promoters and enhancers of target genes, recruiting transcriptional coactivators and promoting gene expression. Key target genes include those encoding components of the electron transport chain (ATP synthase subunits, cytochrome c), fatty acid oxidation enzymes (medium-chain acyl-CoA dehydrogenase, carnitine palmitoyltransferase 1), and transcription factors that amplify the metabolic signal (PGC-1α itself, NRF-1).

The net effect of ERR activation is increased mitochondrial mass and function, enhanced oxidative capacity, greater fatty acid utilization, and improved metabolic flexibility. In tissues like skeletal muscle, this manifests as increased endurance capacity and a shift toward a more oxidative fiber phenotype.

Metabolic Remodeling

By promoting fatty acid oxidation over lipid storage, ERR activation shifts the metabolic balance toward energy expenditure. This effect is particularly relevant in tissues like brown and beige adipose tissue, where ERRs regulate thermogenic programs including uncoupling protein 1 (UCP1) expression.

In heart and skeletal muscle, ERR activation enhances the capacity for oxidative ATP production, potentially improving function under conditions of metabolic stress. The multi-tissue metabolic remodeling induced by pan-ERR agonists like SLU-PP-332 underlies their systemic effects on body composition and insulin sensitivity.

Research on SLU-PP-332 has provided valuable insights into ERR biology and the therapeutic potential of ERR modulation for metabolic diseases. The compound has been extensively characterized in both in vitro and in vivo systems.

Discovery and Characterization

SLU-PP-332 was identified through medicinal chemistry efforts at Saint Louis University (hence "SLU" in the name) to develop selective ERR modulators. Initial characterization demonstrated its selectivity for ERRs over estrogen receptors and other nuclear receptors, establishing it as a useful tool for studying ERR-specific effects.

Biochemical studies confirmed direct binding to ERR proteins and enhancement of their transcriptional activity in reporter gene assays. Structure-activity relationship studies explored how modifications to the core scaffold affected potency and selectivity.

Metabolic Syndrome Studies

Key in vivo studies demonstrated the metabolic benefits of SLU-PP-332 in mouse models of metabolic syndrome. Treatment of diet-induced obese mice produced significant reductions in fat mass without affecting lean mass or food intake, suggesting effects on energy expenditure rather than appetite suppression.

Metabolic profiling revealed increased fatty acid oxidation and oxygen consumption, consistent with enhanced mitochondrial function. Improvements in glucose tolerance and insulin sensitivity were also observed, potentially secondary to reduced adiposity and enhanced muscle metabolic capacity.

Mitochondrial Function

Studies in cultured cells confirmed that SLU-PP-332 increases mitochondrial respiration, consistent with induction of genes involved in oxidative phosphorylation. This has stimulated interest in ERR agonists for conditions involving mitochondrial dysfunction, though these applications remain exploratory.

Gene expression profiling in various tissues has identified transcriptional programs induced by SLU-PP-332, providing insights into ERR target genes and the molecular basis of its metabolic effects.

Exercise Mimetic Research

The effects of SLU-PP-332 on oxidative metabolism and endurance capacity have led to interest in ERR agonists as potential exercise mimetics—compounds that reproduce some benefits of exercise without physical activity. While exercise has far more effects than any single pathway modulator, ERR activation does appear to replicate aspects of exercise training at the molecular and metabolic level.

SLU-PP-332 is a research compound that has been primarily characterized in preclinical studies, with limited data on human safety. As a pan-ERR agonist affecting metabolic gene expression across multiple tissues, several theoretical considerations are relevant for research use. ERRs are expressed in many tissues beyond metabolically active organs, including reproductive tissues, bone, and the brain, and systemic ERR modulation could have effects on these tissues that are not fully characterized. The structural similarity between ERR and estrogen receptor DNA-binding domains raises theoretical questions about potential crosstalk, though SLU-PP-332 has been shown to be selective for ERRs over ERs in biochemical assays. Long-term effects of sustained ERR activation on metabolism, body composition, and organ function have not been fully evaluated. Preclinical studies with SLU-PP-332 have generally not reported overt toxicity at efficacious doses, supporting its use as a research tool compound. The compound is typically dissolved in DMSO for in vitro studies and administered in appropriate vehicles for in vivo research. Standard precautions for handling small molecule research compounds apply. This product is for research purposes only and is not intended for human consumption or therapeutic use. Researchers should conduct appropriate dose-response studies and evaluate tissue-specific effects relevant to their research questions.